Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Naoki Sumiyoshi"'
Autor:
Hidehito Horinouchi, Makoto Nishio, Toyoaki Hida, Kazuhiko Nakagawa, Hiroshi Sakai, Naoyuki Nogami, Shinji Atagi, Toshiaki Takahashi, Hideo Saka, Mitsuhiro Takenoyama, Nobuyuki Katakami, Hiroshi Tanaka, Koji Takeda, Miyako Satouchi, Hiroshi Isobe, Makoto Maemondo, Koichi Goto, Tomonori Hirashima, Koichi Minato, Naoki Sumiyoshi, Tomohide Tamura
Publikováno v:
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Abstract Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients wi
Externí odkaz:
https://doaj.org/article/98ef3513e3d64aad8fdc1d5b550e05c4
Autor:
Akira Ooki, Sachiko Yamamoto, Hisato Kawakami, Tomoki Makino, Akihito Kawazoe, Toshiki Masuishi, Takahiro Tsushima, Motohiro Hirao, Naoki Takegawa, Kaori Hino, Satoru Iwasa, Hiroki Hara, Naoki Sumiyoshi, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Takashi Oshima
Publikováno v:
Journal of Clinical Oncology. 41:337-337
337 Background: E7389-LF is a liposomal formulation of the microtubule dynamics inhibitor, eribulin. Treatment with E7389-LF plus the programmed cell death 1 inhibitor nivolumab may result in an increased antitumor effect through vascular remodeling.
Autor:
Kei Muro, Satoru Iwasa, Naotoshi Sugimoto, Hisato Kawakami, Takashi Oshima, Kensei Yamaguchi, Kaori Hino, Motohiro Hirao, Yukinori Kurokawa, Takeshi Kawakami, Naoki Takegawa, Hiroki Hara, Naoki Sumiyoshi, Daiko Matsuoka, Yohei Otake, Keisuke Yasuda, Takao Takase, Shuya Takashima, Taro Semba, Akihito Kawazoe
Publikováno v:
Journal of Clinical Oncology. 41:339-339
339 Background: Due to a lack of efficacy and long-term survival seen in previously-studied therapies, new therapies for pretreated advanced GC are warranted. E7389-LF is a new formulation that uses liposomes to encapsulate eribulin; this is anticipa
Autor:
Koichi Goto, Mitsuhiro Takenoyama, Koji Takeda, Shinji Atagi, Hidehito Horinouchi, M. Nishio, Tomohide Tamura, Naoyuki Nogami, Kazuhiko Nakagawa, Tomonori Hirashima, Hideo Saka, Naoki Sumiyoshi, Hiroshi Isobe, Hiroshi Sakai, Miyako Satouchi, Toyoaki Hida, Toshiaki Takahashi, Hiroshi Tanaka, Koichi Minato, Makoto Maemondo, Nobuyuki Katakami
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Cancer Medicine, Vol 8, Iss 11, Pp 5183-5193 (2019)
Background Nivolumab is a programmed cell death 1 (PD‐1) receptor inhibitor antibody that enhances immune system antitumor activity. It is associated with longer overall survival (OS) than the standard treatment of docetaxel in patients with previo
Autor:
Koichi Goto, Mitsuhiro Takenoyama, Shiro Fujita, Hideo Saka, Makoto Maemondo, Naoki Sumiyoshi, Hiroshi Tanaka, Yuichiro Ohe, Miyako Satouchi, Makoto Nishio, Koichi Minato, Hiroshi Sakai, Hiroshi Nokihara, Hiroshi Isobe, Kazuhiko Nakagawa, Toshiaki Takahashi, Toyoaki Hida, Tomohide Tamura, Naoyuki Nogami, Koji Takeda, Tomonori Hirashima, Shinji Atagi
Publikováno v:
Cancer Science
Summary Limited treatment options are available for stage IIIB/IV non-small cell lung cancer (NSCLC). Nivolumab, a programmed cell death-1 immune checkpoint inhibitor antibody, has been shown to be effective for the treatment of NSCLC. This study inv
Autor:
Osamu Ezaki, Nobuyo Tsuboyama-Kasaoka, Naoki Sumiyoshi, Norihisa Kato, Yurika Kaseda, Yoshihito Nogusa, Noriyuki Yanaka
Publikováno v:
Bioscience, Biotechnology, and Biochemistry. 69:301-306
Previous studies have suggested that docosahexaenoic acid (DHA), contained in fish oil, prevents brain disease. In the current study, the effect of fish oil feeding on gene expression in the brain was investigated by suppression subtractive hybridiza
Autor:
Shiro Fujita, Koji Takeda, Shinji Atagi, Tomonori Hirashima, Hiroshi Isobe, Hiroshi Nokihara, Yuichiro Ohe, Makoto Nishio, Miyako Satouchi, Toshiaki Takahashi, Makoto Maemondo, Hiroshi Sakai, Hideo Saka, Naoki Sumiyoshi, Hiroshi Tanaka, Toyoaki Hida, Kazuhiko Nakagawa, Koichi Minato, Mitsuhiro Takenoyama, Koichi Goto, Tomohide Tamura, Naoyuki Nogami
Publikováno v:
ESMO Open
Objective Nivolumab is a fully human IgG4 programmed cell death 1 immune checkpoint inhibitor monoclonal antibody approved for the treatment of non-small cell lung cancer (NSCLC). The aim of this study was to evaluate the safety and efficacy of nivol
Autor:
Yoshihito Nogusa, Noriyuki Yanaka, Anna Tanaka, Naoki Sumiyoshi, Norihisa Kato, Yurika Kaseda
Publikováno v:
Bioscience, biotechnology, and biochemistry. 73(12)
Zinc finger protein ZPR1 (ZPR1) binds to eukaryotic translation elongation factor 1alpha (eEF1alpha) in response to growth stimuli, and is also involved in transcription and cell cycle regulation. In this study, we characterized the interaction of ZP
Autor:
Yuko Eguchi, Naoki Sumiyoshi, Norihisa Kato, Noriyuki Yanaka, Yoshihito Nogusa, Tomoaki Haraguchi
Publikováno v:
Bioscience, biotechnology, and biochemistry. 70(7)
A differential display was performed to analyze differential gene expression in the brains of mice in association with dietary high beef-tallow. Consumption of a high beef-tallow diet downregulated the expression of ADP-ribosylation factor-like prote
Publikováno v:
International journal of molecular medicine. 17(3)
A differential display was performed to analyze differential gene expression in the brain of mice in association with dietary high beef tallow. Consumption of a high beef tallow diet up-regulated the expression of zinc finger protein ZPR1 mRNA in the